2-indol-7-yl-acetamide | 39597-67-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-indol-7-yl-acetamide
• 英文别名: 2-(1H-Indol-7-yl)-acetamide；2-(1H-indol-7-yl)acetamide；Indol-7-acetamid
• CAS: 39597-67-6
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: XFMXXEVQVLULNK-UHFFFAOYSA-N

物化性质

• 沸点：
  469.7±28.0 °C(Predicted)
• 密度：
  1.285±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-indol-7-yl-acetamide 在 盐酸 、 potassium tert-butylate 、 乙硫醇 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(1H-Indol-7-yl)-4-(1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-pyrrole-2,5-dione
  参考文献：
  名称：

  The development of potent and selective bisarylmaleimide GSK3 inhibitors

  摘要：

  Many 3-aryl-4-(1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl)maleimides exhibit potent GSK3 inhibitory activity (<100 nM IC50), although few show significant selectivity (>100x) versus CDK2, CDK4, or PKCbetaII. However, combining 3-(imidazo[1,2-a]pyridin-3-yl), 3-(pyrazolo[1,5-a]pyridin-3-yl) or aza-analogs with a 4-(2-acyl-(1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl)) group on the maleimide resulted in very potent inhibitors of GSK3 (less than or equal to5 nM) with >160 to >10,000-fold selectivity versus CDK2/4 and PKCbetaII, These compounds also inhibited tau phosphorylation in cells and were effective in lowering plasma glucose in a rat model of type 2 diabetes (ZDF rat). (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.063
• 作为产物：
  描述：

  tert-butyl 7-formyl-1H-indole-1-carboxylate 在 palladium on activated charcoal 氢氧化钾 、 四丁基氯化铵 、 氢气 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 、 叔丁醇 为溶剂， 20.0~50.0 ℃ 、344.74 kPa 条件下， 生成 2-indol-7-yl-acetamide
  参考文献：
  名称：

  Synthesis of 7-cyano- and 7-acetamido-indoles via cyanocarbonation/hydrogenation of 7-formyl indole

  摘要：

  A procedure for the synthesis of 7-cyano and 7-acetamido indoles via eyanocarbonation/hydrogenation of 7-formyl indole is presented. The process can be efficiently scaled up to provide multigram quantities of the desired compounds in good yield. A small survey of substrate scope indicates that the reaction may prove generally useful for the synthesis of aryl acetonitriles. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0040-4039(03)01322-4

文献信息

• Methods and compounds for treating proliferative diseases
  申请人：——

  公开号：US20040048915A1

  公开（公告）日：2004-03-11

  The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I). 1

  本公开的化合物是式(I)的吲哚咔巴醌，它们是有效的CDK4抑制剂，并且在治疗细胞增殖性疾病，包括癌症方面具有用处。Formula (I).
• Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles
  作者：Thomas A. Engler、Kelly Furness、Sushant Malhotra、Concha Sanchez-Martinez、Chuan Shih、Walter Xie、Guoxin Zhu、Xun Zhou、Scott Conner、Margaret M. Faul、Kevin A. Sullivan、Stanley P. Kolis、Harold B. Brooks、Bharvin Patel、Richard M. Schultz、Tammy B. DeHahn、Kashif Kirmani、Charles D. Spencer、Scott A. Watkins、Eileen L. Considine、Jack A. Dempsey、Catherine A. Ogg、Nancy B. Stamm、Bryan D. Anderson、Robert M. Campbell、Vasu Vasudevan、Michelle L. Lytle

  DOI：10.1016/s0960-894x(03)00461-x

  日期：2003.7

  The synthesis and CDK inhibitory properties of a series of indolo[6,7-a]pyrrolo[3,4-c]carbazoles is reported. In addition to their potent CDK activity, the compounds display antiproliferative activity against two human cancer cell lines. These inhibitors also effect strong G1 arrest in these cell lines and inhibit Rb phosphorylation at Ser780 consistent with inhibition of cyclin D1/CDK4.

  报道了一系列吲哚[6，7-a]吡咯并[3，4-c]咔唑的合成和CDK抑制性能。这些化合物除了具有强大的CDK活性外，还具有针对两种人类癌细胞系的抗增殖活性。这些抑制剂还影响这些细胞系中的强G1阻滞，并抑制Ser780处的Rb磷酸化，这与抑制细胞周期蛋白D1 / CDK4一致。
• Purine derivatives as kinase inhibitors
  申请人：Engler Albert Thomas

  公开号：US20050090483A1

  公开（公告）日：2005-04-28

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了式I的激酶抑制剂。
• Kinase inhibitors
  申请人：Albaugh Ann Pamela

  公开号：US20050288321A1

  公开（公告）日：2005-12-29

  The present invention provides kinase inhibitors of Formula (I).

  本发明提供了化合物式(I)的激酶抑制剂。
• PURINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Engler Thomas Albert

  公开号：US20090105229A1

  公开（公告）日：2009-04-23

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了化合物I的激酶抑制剂。